Participated · Series F · Apr 2026

Calyxo develops the CVAC System, an all-in-one aspiration-based platform that uses irrigation and vacuum aspiration to continuously clear kidney stone fragments during and after laser lithotripsy. The CVAC System was FDA-cleared in 2024 and aims to enable more complete stone clearance, which the company says drives improved clinical outcomes. Clinical, preclinical, and health economic evidence cited by Calyxo report low residual stone volume, improved procedural efficiency, and reductions in downstream healthcare utilization and cost. The company announced that over 40,000 patients have been treated with the CVAC System, signaling growing physician adoption. Calyxo plans to use newly raised capital to expand commercial infrastructure, generate further clinical and health-economic evidence through ongoing and future studies, and continue product innovation. The company describes itself as focused on paradigm-shifting solutions to improve kidney stone care.

Led · Equity · Jan 2025

Aerin Medical is a privately held, venture-backed medical device company headquartered in Mountain View, California, focused on expanding access to relief for patients with chronic ENT conditions. Its products VivAer® (for nasal airway obstruction) and RhinAer® (for chronic rhinitis) leverage a proprietary temperature-controlled technology as alternatives to invasive surgery. The company reports that more than 150,000 patients have been treated with its products to date. Aerin said it will use recent financing to drive additional commercial expansion, invest in R&D, and further expand its clinical evidence portfolio. Management emphasized plans to deepen penetration in markets for nasal obstruction and chronic rhinitis. Financially, Aerin completed a $32.5 million equity financing and secured a debt facility to refinance existing debt and provide additional financial flexibility. Aerin Medical commercializes non-invasive, temperature-controlled radiofrequency treatments for chronic nasal conditions through its VivAer and RhinAer products. VivAer, launched in the U.S. in 2018, treats nasal airway obstruction (which the company cites as affecting 20 million Americans); RhinAer launched in 2020 for chronic rhinitis. More than 60,000 patients have been treated with Aerin products to date, and the company reported 10 new peer-reviewed clinical publications in the last year. Aerin is privately held and venture-backed, with U.S. offices in California and Texas. The company intends to use new financing to scale commercialization and expand market access to meet physician and patient demand. Aerin Medical develops non-invasive, office-based treatments for chronic nasal airway conditions. Its FDA-cleared VivAer® Stylus treats nasal airway obstruction and the RhinAer® Stylus treats chronic rhinitis using a proprietary temperature-controlled technology. The company provides tissue-sparing solutions for otolaryngologists (ENTs) to improve patient quality of life. Aerin is venture-backed and has offices in Sunnyvale, California and Austin, Texas. The company announced a leadership change with the appointment of Matt Brokaw as President and CEO. Proceeds from the financing will be used to accelerate commercial growth, support new clinical studies, and develop new products. Aerin Medical, led by CEO Fred Dinger and based in Austin, Texas, develops and commercializes minimally invasive treatments for nasal airway disorders. Its flagship product is the Vivaer Nasal Airway Remodeling System, a physician‑office procedure for treating nasal obstruction. The company focuses on improving patients' quality of life through disruptive, office‑based interventions. Financially, Aerin closed a $50M non‑dilutive term loan with CRG LP, receiving $35M at closing and up to $15M more in milestones. Approximately $16.5M of the proceeds were used to retire existing debt. The remaining funds are designated to accelerate sales and marketing reach and to support the launch of its next product. Aerin Medical is a medical device company that has developed a non-invasive treatment platform using low-power radiofrequency energy to remodel nasal soft tissues and address nasal congestion. The platform is designed for use in the physician’s office to treat underlying causes of nasal breathing disorders. Led by CEO Fred Dinger, Aerin operates offices in Austin, Texas; Sunnyvale, California; and Singapore. The company is backed by healthcare investors KCK Group and Targeted Technology. Aerin closed a $15M venture loan facility provided by Horizon Technology Finance Corporation. The company will use the proceeds for general working capital purposes.

Led · Equity · Dec 2024

Founded in 2014, OSSIO aims to transform orthopedic surgery by replacing traditional metal implants with its proprietary OSSIOfiber Intelligent Bone Regeneration Technology. The company’s bio-integrative implants are designed to provide strong fixation while naturally integrating with bone, eliminating the need for hardware removal and improving patient outcomes. Product development and manufacturing are conducted in Caesarea, Israel, while commercial operations are headquartered in Palmetto, Florida. Management plans to use additional growth capital to accelerate global expansion of the technology across the multibillion-dollar orthopedic fixation market. OSSIO positions itself as a disruptive alternative for patients, physicians, providers and payors seeking better clinical and economic value. Although no revenue or user metrics were disclosed, the firm emphasizes rapid commercialization and international scaling. The recent financing partnership underscores OSSIO’s focus on maintaining its mission while gaining the resources required for broader market penetration.

Participated · Equity · Sep 2024

ACTO offers an AI-first IFE platform focused on closing gaps in HCP omnichannel engagement for life sciences commercial teams. Its product roadmap centers on the LAICA suite, announced in 2022, and integrated Generative AI capabilities. Planned GenAI features include field rep real-time knowledge assistance, simulated rep–manager roleplay and coaching, commercial learning content creation assistance, and commercial leader field insight assistance. The company announced a dedicated US$10M investment into GenAI to accelerate those capabilities. Funding for this effort comes from ACTO’s venture capital backers alongside public and cloud partners, and the company is piloting real-world use cases with customers via the AWS Jumpstart Program. Executives and investors frame ACTO as an early AI-focused category leader on the commercial side of life sciences, citing work that began as early as 2019. ACTO provides an AI-powered omnichannel learning and enablement SaaS platform that helps global life‑sciences companies educate and engage field teams and learners across the care continuum. Commercial and clinical leaders use ACTO to deliver unified educational experiences and sales enablement at scale. The company maintains a network of partnerships with content agencies, data providers, and technology companies to build an ecosystem for life sciences. ACTO recently introduced a conversational assistant, LAICA™, as part of its product roadmap to make commercial learning easier and more engaging. The company is experiencing robust user and revenue growth, reporting a 500% increase in annual recurring revenue since 2018 and total invested capital exceeding US$30 million. Proceeds from its latest financing will be used to accelerate growth, expand capabilities, and pursue business and partnership opportunities. ACTO builds an AI-powered mobile platform that educates and supports stakeholders in life sciences, enabling training, content delivery, and sales enablement. The platform offers self-paced modules called ActionPacks containing multimedia, quizzes, 3D content, authoring tools, and event engagement features. ACTO has launched conversational AI capabilities that surface information about drugs and medical devices to support doctors, nurses, and other providers. Managers can certify reps with digital signatures and PDF certificates, run assessments, and deliver AI-personalized notifications and reference guides. The platform includes deep search, multi-channel integrations, permissioning, tracked mail/text links, and CRM integrations that generate reports by individual, team, and territory. ACTO says tens of thousands of reps rely on it across 50 life sciences companies, including AstraZeneca, Teleflex, and Philips Respironics. The company closed an $11.5 million funding round to bolster these capabilities and accelerate digital engagement.

Participated · Series D · Jun 2024

Eko Health develops AI-enhanced digital stethoscopes and companion software that combine acoustic heart and lung sounds with ECG to aid detection of cardiac conditions. Founded in 2013, the company has sold its stethoscope to more than 500,000 physicians and healthcare providers and has amassed chest-sound and ECG data from millions of patients to train its algorithms. Eko has received FDA clearance for three algorithms, including an April clearance to help detect early signs of heart failure and recent clearance to detect heart murmurs. The company positions its AI to improve the consistency and accuracy of routine exams, bringing cardiology-level assessment to primary care and frontline clinicians. Eko plans to use the new funding to train algorithms to detect pulmonary conditions such as asthma and pneumonia and to expand sales of its device and software outside the U.S. Clinical validation includes a Massachusetts General Hospital study that found Eko’s AI identified more than twice as many patients with heart disease compared to primary care doctors. Eko develops smart stethoscopes and an FDA-cleared AI platform used by hundreds of thousands of healthcare professionals worldwide to detect and monitor heart and lung disease. The company collects phonocardiogram (PCG) and electrocardiogram (ECG) data with its DUO ECG + Digital Stethoscope to train machine-learning algorithms. Eko has partnered with Lifespan Health System’s Cardiovascular Institute to develop an algorithm that detects and stratifies pulmonary hypertension (PH). The goal is an easy-to-deploy, low-cost tool that enables earlier and more accurate identification of PH and improves clinical decision-making. Eko’s work aims to reduce long diagnostic delays and provide a scalable alternative to costly, invasive gold-standard tests. Eko develops digital stethoscopes with features such as noise-canceling, recording, and visualization of heart sounds alongside FDA-cleared clinical support algorithms. In 2020 the FDA granted 510(k) clearance to a suite of Eko algorithms for detecting heart murmurs and atrial fibrillation, and additional clinical results were published in The Journal of the American Heart Association in 2021. The company has launched Eko App, which integrates those algorithms to capture heart sounds and ECG data in the background and provide immediate analysis or summary reports in the exam room. Eko positions this software as a clinical decision support system to help clinicians—particularly in ambulatory and rural primary-care settings—interpret cardiac data. The company is pursuing broader screening for structural heart disease and heart failure, and an independent NHS trial with Mayo Clinic collaborators showed an algorithm could flag LVEF around 40% after 15 seconds of listening, though that algorithm has not yet received FDA clearance for clinical use. Eko plans to commercialize these capabilities and continue product development backed by recent funding. Eko develops a platform that pairs advanced sensors and clinician- and patient-facing software with AI algorithms to elevate detection and monitoring of cardiac and respiratory disease. The company reinvented the stethoscope and introduced a combined handheld digital stethoscope and electrocardiogram (ECG), and its AI analysis is FDA-cleared to help detect heart rhythm abnormalities and structural heart disease. Its FDA-cleared platform is used by tens of thousands of clinicians treating millions of patients around the world, both in-person and via telehealth. Eko has recently launched a telehealth platform and achieved product milestones including clearance of its AI suite. The company plans to expand in-clinic use of its telehealth and AI platform and to launch a home monitoring program for cardiopulmonary patients. Eko is headquartered in Oakland, California and announced new funding to accelerate growth. Eko develops advanced sensors, clinician and patient software, and AI algorithms integrated into a digital stethoscope platform for cardiac and respiratory disease detection and monitoring. The company’s cardiac AI algorithms are cleared by the U.S. Food and Drug Administration and it has launched an AI-powered telehealth platform. Its technology is used by tens of thousands of clinicians, in more than 1,000 institutions worldwide, treating millions of patients. Eko is headquartered in Oakland, California and is privately held. The company has strategic investors including ARTIS Ventures, NTT Venture Capital, DigiTx Ventures, Mayo Clinic, and Sutter Health. Ongoing clinical validation with academic partners is a stated priority to extend cardiologist-level auscultation to general practitioners.